Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On October 30, 2012, Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer
of Seattle Genetics, Inc. ("Seattle Genetics" or "the Company"), informed the
Company of his resignation in connection with his retirement for a family health
matter. Dr. Reynolds will continue to serve as the Company's Chief Medical
Officer until December 31, 2012. Dr. Reynolds has been a key contributor at
Seattle Genetics, notably through his leadership of the Company's clinical and
regulatory teams during the development and approval of ADCETRIS®. The Company
has started a search for a replacement to Dr. Reynolds and anticipates a
seamless transition of responsibilities over the next several months.
Add
SGEN to Portfolio
Set Alert
Email to a
Friend